RXRX
RECURSION PHARMACEUTICALS, INC.
+0.27 (+8.62%)3.47USD13.4M成交股數1.9B市值–本益比(近四季)33.8股價營收比-60.1%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 7.7M-48% | 6.5M+42% | 5.2M-80% | 19.2M+33% | 14.7M+7% | 4.5M-57% | 26.1M+137% | 14.4M+19% | 13.8M | 10.5M | 11.0M | 12.1M |
| 營業成本 | 11.5M | 12.5M | 14.7M | 20.2M | 21.8M | 12.8M | 12.1M | 9.2M | 11.2M | 10.9M | 9.4M | 12.4M |
| 毛利 | −3.8M-46% | −6.0M-27% | −9.5M-168% | −938K-118% | −7.1M-370% | −8.2M+2298% | 14.0M+756% | 5.2M-1762% | 2.6M | −344K | 1.6M | −314K |
| 毛利率 | -49.8% | -93.0% | -183.8% | -4.9% | -48.0% | -181.4% | 53.7% | 36.2% | 19.1% | -3.3% | 14.8% | -2.6% |
| 研發費用 | 89.6M | 87.9M | 121M | 129M | 130M | 98.3M | 74.6M | 73.9M | 67.6M | 70.0M | 55.1M | 46.7M |
| 銷售管理費用 | 41.5M | 34.6M | 41.6M | 46.7M | 54.7M | 77.2M | 37.8M | 31.8M | 31.4M | 29.2M | 28.3M | 22.9M |
| 營業利益 | −135M-29% | −129M-30% | −172M+75% | −176M+75% | −191M+99% | −184M+85% | −98.4M+20% | −101M+44% | −96.3M | −99.6M | −81.7M | −69.9M |
| 營業利益率 | -1,759.7% | -1,985.6% | -3,327.6% | -916.8% | -1,297.9% | -4,042.4% | -377.1% | -697.4% | -698.4% | -945.1% | -741.7% | -575.8% |
| 稅後淨利 | −131M-35% | −118M-34% | −162M+69% | −172M+76% | −202M+122% | −179M+92% | −95.8M+25% | −97.5M+49% | −91.4M | −93.0M | −76.7M | −65.3M |
| 淨利率 | -1,708.0% | -1,815.6% | -3,135.3% | -894.2% | -1,373.3% | -3,935.5% | -367.5% | -676.6% | -662.4% | -883.1% | -696.4% | -538.4% |
| 稀釋 EPS | -0.25-50% | -0.22-61% | -0.36+6% | -0.41+2% | -0.50+28% | -0.56+30% | -0.34-11% | -0.40+18% | -0.39 | -0.43 | -0.38 | -0.34 |
| 稀釋股數 | 532M | 529M | 447M | 417M | 403M | 274M | 283M | 242M | 236M | 214M | 201M | 192M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 546M | 654M | 660M | 525M | 500M | 594M | 428M | 474M | 296M | 387M | 406M | 473M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 1.2B | 1.3B | 1.4B | 1.3B | 1.3B | 1.4B | 726M | 776M | 558M | 631M | 667M | 627M |
| 有息負債 | 4.8M | 7.2M | 11.9M | 14.2M | 16.4M | 19.0M | 20.5M | 22.9M | – | – | – | – |
| 總負債 | 298M | 315M | 353M | 383M | 371M | 414M | 202M | 191M | 157M | 193M | 198M | 197M |
| 股東權益 | 915M | 1.0B | 1.0B | 919M | 934M | 1.0B | 525M | 584M | 401M | 438M | 469M | 430M |
| 負債比 | 24.5% | 23.5% | 25.2% | 29.4% | 28.4% | 28.6% | 27.8% | 24.7% | 28.1% | 30.6% | 29.7% | 31.4% |
| 淨現金(現金 − 有息負債) | 541M | 647M | 648M | 511M | 484M | 575M | 407M | 451M | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −81.1M | – | – | −132M+29% | – | – | – | −102M | – | – | −73.3M |
| 資本支出 | – | 258K | – | – | 1.8M | – | – | – | 6.7M | – | – | 5.2M |
| 自由現金流 | – | −81.4M | – | – | −134M+23% | – | – | – | −109M | – | – | −78.5M |
| 折舊攤銷 | – | 19.7M | – | – | 19.3M | – | – | – | 7.4M | – | – | 3.7M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -1,257.1% | – | – | -907.4% | – | – | – | -789.9% | – | – | -646.9% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 74.7M
| Reportable | 74.7M | 100.0% | +26.9% |
|---|
地區2025 年度 · 74.7M
| 美國 | 39.3M | 52.7% | -31.4% |
|---|---|---|---|
| 英國 | 35.3M | 47.3% | +3013.4% |
產品／服務2025 年度 · 74.7M
| License And Service | 74.3M | 99.4% | +27.0% |
|---|---|---|---|
| Grant | 425K | 0.6% | +21.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 74.7M | +26.9% | −645M | -863.4% | -1.44 | −378M |
| FY2024 | 58.8M | +32.0% | −464M | -788.0% | -1.69 | −373M |
| FY2023 | 44.6M | +11.9% | −328M | -736.0% | -1.58 | −300M |
| FY2022 | 39.8M | +291.5% | −239M | -601.0% | -1.36 | −121M |
| FY2021 | 10.2M | +156.9% | −186M | -1,832.2% | -1.49 | −198M |
| FY2020 | 4.0M | +70.8% | −87.0M | -2,196.0% | -3.99 | −51.2M |
| FY2019 | 2.3M | – | −61.9M | -2,668.3% | -2.87 | −61.0M |